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ORIGINAL RESEARCH
Loss of Endothelial Endoglin Promotes High-
Output Heart Failure Through Peripheral 
Arteriovenous Shunting Driven by VEGF Signaling
Simon Tual-Chalot, Maria Garcia-Collado, Rachael E. Redgrave, Esha Singh, Benjamin Davison, Catherine Park, Hua Lin,  
Saimir Luli, Yi Jin, Yixin Wang, Allan Lawrie, Lars Jakobsson,* Helen M. Arthur*
RATIONALE: ENG (endoglin) is a coreceptor for BMP (bone morphogenetic protein) 9/10 and is strongly expressed in endothelial 
cells. Mutations in ENG lead to the inherited vascular disorder hereditary hemorrhagic telangiectasia characterized by local 
telangiectases and larger arteriovenous malformations (AVMs); but how ENG functions to regulate the adult vasculature is 
not understood.
OBJECTIVE: The goal of the work was to determine how ENG maintains vessel caliber in adult life to prevent AVM formation 
and thereby protect heart function.
METHODS AND RESULTS: Genetic depletion of endothelial Eng in adult mice led to a significant reduction in mean aortic blood 
pressure. There was no evidence of hemorrhage, anemia, or AVMs in major organs to explain the reduced aortic pressure. 
However, large AVMs developed in the peripheral vasculature intimately associated with the pelvic cartilaginous symphysis—
a noncapsulated cartilage with a naturally high endogenous expression of VEGF (vascular endothelial growth factor). The 
increased blood flow through these peripheral AVMs explained the drop in aortic blood pressure and led to increased cardiac 
preload, and high stroke volumes, ultimately resulting in high-output heart failure. Development of pelvic AVMs in this region 
of high VEGF expression occurred because loss of ENG in endothelial cells leads to increased sensitivity to VEGF and a 
hyperproliferative response. Development of AVMs and associated progression to high-output heart failure in the absence of 
endothelial ENG was attenuated by targeting VEGF signaling with an anti-VEGFR2 (VEGF receptor 2) antibody.
CONCLUSIONS: ENG promotes the normal balance of VEGF signaling in quiescent endothelial cells to maintain vessel caliber—
an essential function in conditions of increased VEGF expression such as local hypoxia or inflammation. In the absence 
of endothelial ENG, increased sensitivity to VEGF drives abnormal endothelial proliferation in local regions of high VEGF 
expression, leading to AVM formation and a rapid injurious impact on heart function.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: arteriovenous malformations ◼ endoglin ◼ endothelial cells ◼ hypoxia ◼ vascular diseases
Meet the First Author, see p 160
E
NG (endoglin) protein (also known as CD105 [clus-
ter of differentiation 105]) is a coreceptor for mem-
bers of the TGF (transforming growth factor)-β 
superfamily of ligands, with high affinity for BMP (bone 
morphogenetic protein) 9 and 10.1–3 ENG is expressed 
in vascular endothelial cells (ECs), mesenchymal stem 
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cells, myofibroblasts, syncytiotrophoblasts, and macro-
phages.4–6 In ECs, ENG promotes BMP 9/10 signaling 
through the receptor ACVRL1 (also known as ALK1 
[activin receptor-like kinase 1]) to regulate develop-
mental angiogenesis,7 endothelial migration, and cell 
shape.8,9 Mutations in ENG or ACVRL1 lead to the inher-
ited vascular disorder, hereditary hemorrhagic telangiec-
tasia (HHT), a disease characterized by arteriovenous 
malformations (AVMs),10 which are direct connections 
between arteries and veins. We and others have shown 
using preclinical models that developmental or patho-
logical angiogenesis is an essential trigger driving the 
vascular remodeling associated with AVM formation in 
the developing retina, adult brain, and dermal wound 
healing.11–14 It is also well established that ENG plays a 
critical role in angiogenesis, as ubiquitous loss of ENG 
(Eng−/−) leads to major angiogenesis defects in the devel-
oping embryo and early embryonic lethality.15 Neverthe-
less, the molecular and cellular mechanisms that drive 
abnormal vascular remodeling events in quiescent blood 
vessels to generate AVMs in adult HHT patients remain 
obscure. Furthermore, there is a growing interest in ENG 
in cardiovascular disease more broadly, as the extracel-
lular domain of ENG known as soluble ENG is found 
at increased levels in the circulation (most likely due to 
shedding from the EC surface) in preeclampsia,16 hyper-
tension,17 hypercholesterolemia,18 and in patients with 
increased left heart filling pressures.19 However, whether 
soluble ENG is simply a biomarker of disease or has an 
important biological role in regulating the mature vascu-
lature is unknown. These studies are severely hampered 
by our lack of understanding of the full-length transmem-
brane form of ENG in quiescent mature ECs and specifi-
cally whether it plays a key role in maintaining the mature 
cardiovasculature, which is the focus of this investigation.
Nonstandard Abbreviations and Acronyms
ALK1 activin receptor-like kinase 1
AVM arteriovenous malformation
BMP bone morphogenetic protein
BP blood pressure
EC endothelial cell
EdU 5-ethynyl-2-deoxyuridine
ENG endoglin
ERK extracellular signal-regulated kinase
HHT hereditary hemorrhagic telangiectasia
HOHF high-output heart failure
TGF transforming growth factor
VEGF vascular endothelial growth factor
Novelty and Significance
What Is Known?
• Endoglin is a coreceptor in endothelial cells that regu-
lates developmental and pathological angiogenesis.
• Mutations in endoglin lead to hereditary hemorrhagic 
telangiectasia—a disease characterized by arteriove-
nous malformations (AVMs).
• How endoglin regulates quiescent vasculature in adult 
life is not yet understood.
What New Information Does This Article  
Contribute?
• Endothelial endoglin is essential to maintain adult vas-
cular architecture to prevent AVM formation and asso-
ciated high-output heart failure (HOHF).
• In the absence of endothelial endoglin in adult life, 
AVMs rapidly develop in the hypoxic cartilage of the 
pubic symphysis.
• Systemic anti-VEGFR2 (VEGF receptor 2) therapy 
prevents AVM formation and attenuates progression 
to HOHF.
Endoglin is a coreceptor that promotes BMP (bone mor-
phogenetic protein) 9/10 signaling in endothelial cells 
to regulate developmental and pathological angiogene-
sis. Mutations in endoglin lead to hereditary hemorrhagic 
telangiectasia —an inherited vascular disorder charac-
terized by AVMs, which are localized direct connections 
between arteries and veins. In this novel mouse model, 
loss of endoglin in adult endothelial cells rapidly leads 
to pelvic AVMs, likely driven by high endogenous VEGF 
(vascular endothelial growth factor) levels in the hypoxic 
pelvic cartilage. We show enhanced phospho-ERK 
(extracellular signal-regulated kinase)/VEGF signaling 
responses in endothelial cells in the absence of endog-
lin in vitro and confirm that enhanced phospho-ERK is 
also present in endothelial cells of AVMs in vivo. AVMs 
are associated with loss of aortic pressure and HOHF—
a poorly understood disease with high mortality risk. 
Systemic anti-VEGFR2 therapy in vivo protects against 
localized AVM formation and attenuates progression to 
HOHF. This unique model opens up new opportunities 
to investigate both hereditary hemorrhagic telangiecta-
sia and HOHF pathology and to evaluate novel thera-
peutic interventions. Furthermore, our findings strongly 
support the premise that AVMs in patients with heredi-
tary hemorrhagic telangiectasia are likely to develop in 
areas of high local VEGF expression, known to occur in 
infection, wounding, and in hypoxic conditions.
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METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
All animal experiments were performed under European 
legislation and approved by the Animal Ethics Committees of 
Newcastle University and Karolinska Institute. Mice (Cdh5(PAC)-
CreERT2;Engfl/fl) were generated as described previously,11 
maintained in a C57BL/6 background on standard chow, 
and crossed with transgenic fluorescent reporter mouse lines 
B6.Cg-Gt(ROSA)26Sortm3(CAG-EYFP)Hze/J (No. 007903; Jackson 
Laboratory) for in vivo lineage tracing. Male and female mice aged 
between 8 and 24 weeks were given tamoxifen (2 mg/day) either 
by intraperitoneal injection for 5 consecutive days or by gavage 
for 3 consecutive days to deplete ENG in ECs. Tamoxifen-treated 
Engfl/fl littermates were used as controls. Mice were assigned to 
experiments based on genotype, but identities were then ano-
nymized so that researchers were normally blinded to genotype. 
To measure cell proliferation, intraperitoneal injections of 20 mg/
kg of 5-ethynyl-2-deoxyuridine (EdU) were given at day 0 (first 
day of tamoxifen administration) and days 2, 4, 6, 8, and 10. Mice 
were humanely killed at day 13 and tissues analyzed using the 
Click-iT EdU imaging kit (C10338; ThermoFisher Scientific). All 
image processing and analysis was performed using ImageJ soft-
ware. Antibody DC101 was a kind gift from Eli Lilly and deliv-
ered intraperitoneally at 40 mg/kg as described in the main text. 
Western blot, quantitative polymerase chain reaction, tissue analy-
ses, and cardiac magnetic resonance imaging were performed as 
described previously6,11,20–22 with further details and data analysis 
methods available in Online Data Supplement.
RESULTS
To investigate the role of endothelial ENG in established 
mature cardiovasculature, we genetically depleted ENG 
in adult Cdh5(PAC)-CreERT2;Engfl/fl mice using transient 
tamoxifen treatment to generate endothelial-specific Eng 
knockout mice (Eng-iKOe). Loss of endothelial ENG pro-
tein in tissues known to be affected in HHT (lung, liver, 
brain, and gut) was confirmed by immunofluorescent stain-
ing (Online Figure IA). The effect of ENG depletion from 
vascular endothelium was striking; Eng-iKOe mice rapidly 
developed a grossly enlarged heart and cardiomyocyte 
hypertrophy (Figure 1A through 1D), while ventricular wall 
thickness was unchanged, consistent with eccentric car-
diac remodeling (Figure 1E). Myocardial tissue also showed 
upregulation of ANP (Nppa), BNP (Nppb), and Acta1 genes, 
associated with progression to cardiac failure (Figure 1F), 
but congestive heart failure appeared unlikely because 
there was no accompanying change in peripheral oxygen 
saturation, heart rate, or tissue edema (Online Figure II).
Cardiac magnetic resonance imaging was performed 
in a longitudinal 5-week study to evaluate the impact of 
endothelial ENG depletion on heart function and revealed 
a progressive increase in end diastolic and end systolic 
volumes in both left and right ventricles, associated with 
increased stroke volumes. These changes occurred ini-
tially in the right ventricle but were subsequently mirrored 
in the left ventricle (Figure 2) and accompanied by 
increased left ventricular mass and increased cardiac 
output (Online Table I). Follow-up analyses showed that 
ventricular volumes further increased over 12 weeks, 
accompanied by a significant drop in ejection fraction 
(Online Figure IIIA). This phenotype is characteristic of 
high-output heart failure (HOHF). Disease progression 
occurred in a highly reproducible way affecting 100% 
male and female Eng-iKOe mice and was followed by sig-
nificant weight loss and >70% mortality at 24 weeks after 
endothelial ENG knockdown (Online Figure IIIC and IIID). 
To investigate the primary effects resulting from loss of 
endothelial ENG, we performed subsequent assessment 
of the cardiovascular phenotype no later than 5 weeks 
after ENG depletion, before any clinical signs of ill health.
Clinically, HOHF can result from loss of vascular resis-
tance. Aortic telemetry was, therefore, used to investigate 
real-time changes in aortic blood pressure (BP) in response 
to loss of endothelial ENG. Daily aortic BP cycles in parallel 
with mouse activity, being the highest at night. However, 
ENG knockdown led to a significant reduction in mean 
aortic BP, demonstrating loss of peripheral vascular resis-
tance compared with baseline (Figure 3A). Consistent with 
this finding, cardiac-conductance catheter measurements 
showed reduced end systolic left ventricular BP in Eng-
iKOe mice at 1 week after endothelial ENG knockdown 
compared with controls (Online Table II). This was accom-
panied by an increased right ventricular contractility (Max 
dp/dt) and increased right ventricular end diastolic pres-
sure indicating an increase in cardiac preload in Eng-iKOe 
mice (Online Table II). This phenotype is consistent with a 
major loss of systemic vascular resistance associated with 
increased venous return and greater right ventricular filling 
pressure. These data suggest that increased preload drives 
the observed eccentric cardiac enlargement, as predicted 
by the Frank-Starling law, resulting in high cardiac output.
As reduction in systemic aortic BP may arise as a con-
sequence of anemia or arteriovenous shunting, the pheno-
type of Eng-iKOe mice was investigated accordingly. There 
was no sign of hemorrhage in Eng-iKOe mice at 1 month 
after ENG depletion, and blood analysis showed normal 
hematocrit and hemoglobin levels, excluding anemia as 
a potential cause of HOHF (Online Table III). Because 
HHT1 (the form of HHT attributable to mutations in ENG) 
is associated with development of pulmonary AVMs,23 
we next evaluated pulmonary arteriovenous shunting 
between venous and arterial beds in Eng-iKOe mice. Flu-
orescent microspheres (15 µm3), which are too large to 
pass through normal murine pulmonary capillaries, were 
injected into the tail vein 1 month after ENG knockdown. 
All beads were found efficiently trapped in pulmonary vas-
culature of both control and Eng-iKOe mice (Figure 3B), 
with no beads detected in systemic organs (brain, kid-
ney, and liver) consistent with the absence of pulmonary 
AVMs and also in line with the increased right ventricular 
pressure that we observed previously (Online Table II). In 
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addition, blood taken from Eng-iKOe mice showed normal 
oxygen saturation compared with controls (Online Table 
III), while oximetry confirmed similar peripheral oxygen 
saturation in control and Eng-iKOe mice (Online Figure II). 
All these data are in agreement with the conclusion that 
there are no pulmonary AVMs in Eng-iKOe mice.
HOHF is a rare complication of HHT mainly sug-
gested to be a consequence of arteriovenous shunting in 
the liver.24 Although hepatic AVMs are more frequent in 
HHT2 (ALK1 patients) than HHT1 (ENG patients) they 
could potentially develop after endothelial ENG depletion 
and contribute to the observed reduction in aortic BP. To 
evaluate this possibility, microbeads were delivered to the 
systemic circulation via the left cardiac ventricle. Larger 
45-µm3 beads were required for this analysis because 
15-µm3 beads readily passed through the hepatic vascu-
lature from the arterial to the venous side in control mice 
(not shown), consistent with the large sinusoidal capil-
laries and the presence of natural arterioportal venular 
anastomoses in normal rodent liver.25 These large beads 
were efficiently trapped in the systemic vasculature in 
control mice but readily crossed to the lung following 
endothelial ENG depletion leading to a massive accu-
mulation of beads in lungs of Eng-iKOe mice (Figure 3C 
Figure 1. Loss of endothelial ENG (endoglin) leads to high cardiac output and cardiac hypertrophy associated with expression 
of heart failure markers.
A, Eng-iKOe mice show a progressive heart enlargement. This example is 8 wk after endothelial ENG depletion. Scale bar=2 mm. B, Hearts from 
Eng-iKOe mice are significantly larger and heavier than controls 5 wk after ENG depletion (nt5/group). C and D, Heart sections were stained 
with fluorescein-conjugated wheat germ agglutinin to outline individual cardiomyocytes, which were significantly larger 5 wk after ENG depletion 
compared with controls (n=3/group). Scale bar=20 µm. E, Average wall thickness of end diastolic left and right free wall measured by cardiac 
magnetic resonance imaging 5 wk after ENG depletion (n=6/group). F, Quantitative polymerase chain reaction shows increased levels of Anp, Bnp, 
and Acta1 in Eng-iKOe heart tissue 5 wk after ENG depletion (n=5/group). All data were analyzed by 2-way ANOVA with Bonferroni correction.
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and 3D). This pointed to de novo arteriovenous shunt-
ing at t1 sites in the systemic vasculature. To map any 
changes in liver vessel architecture, vascular tracing was 
performed using radio-opaque microfil and tissues ana-
lyzed by micro-CT. However, no vascular malformations 
were seen in livers of Eng-iKOe mice 1 month after ENG 
depletion (Online Figure IVA). In parallel, vascular tracing 
of the skin, gastrointestinal tract, spleen, and kidney was 
performed using latex. This compound is reportedly too 
large to pass from arteries to veins in mice and has been 
Figure 2. Loss of endothelial ENG (endoglin) leads to increased end systolic and end diastolic volumes and increased stroke 
volumes in left and right ventricles.
Longitudinal study of heart function in control and Eng-iKOe mice using cardiac magnetic resonance imaging demonstrates a progressive 
increase in right and left ventricular volumes over 5 wk following endothelial ENG depletion (A–C) compared with control mice (D–F). Significant 
changes are observed in the right ventricle within 3 wk of endothelial ENG loss, while similar changes occur in the left ventricle by 4 wk (n=6/
group). All data were analyzed by 2-way ANOVA with Bonferroni correction.
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Figure 3. Rapid loss of aortic blood pressure (BP) and extensive left-to-right shunting from the systemic to the pulmonary 
vasculature in Eng-iKOe mice.
A, Aortic telemetry shows the diurnal rhythm of BP in both groups of mice, with higher BP during the night when mice are the most active and lower 
BP during the day when they are asleep. Baseline measurements were made for 3 d before tamoxifen was delivered once daily for 5 consecutive 
days, and mean aortic BP subsequently falls in Eng-iKOe mice (n=4/group). Data analyzed by 2-way ANOVA with Bonferroni correction. *P<0.05, 
with the full set of P in Online Table V. B, Small fluorescent microbeads (15 µm3) injected into the tail vein of Eng-iKOe and control mice are all 
efficiently trapped in the lung vasculature, indicating absence of pulmonary arteriovenous malformations. No beads were detected in brain, kidney, or 
liver (nt6/group). C, Large fluorescent microbeads (45 µm3) injected into the left ventricle of control mice are efficiently trapped in the vasculature of 
the systemic organs (brain, kidney, and liver) with few beads reaching the lungs. However, in Eng-iKOe mice, the microbeads rapidly reach the lungs 
within 1 min of bead delivery to the left ventricle (nt8/group). Scale bar=2 mm. D, Quantification of microbeads used in C, reaching lungs of Eng-
iKOe and control mice, analyzed by Mann-Whitney U test (nt7/group). LL indicates left lung; and RL, right lung.
D
ow
nloaded from
 http://ahajournals.org by on March 9, 2020
O
R
IG
IN
AL R
ES
EAR
C
H
Tual-Chalot et al Endoglin and High-Output Heart Failure
Circulation Research. 2020;126:243–257. DOI: 10.1161/CIRCRESAHA.119.315974 January 17, 2020  249
widely used to visualize arteriovenous connections. How-
ever, we observed that latex perfusion data need to be 
interpreted with caution as latex readily passes from the 
distal tail artery to tail veins and from distal leg arteries to 
femoral veins, reaching the vena cava in 80% (12 of 15) 
control mice and on occasion filling smaller veins in a ret-
rograde manner. Therefore, only sites of direct antegrade 
flow of latex from arteries into veins were recorded to 
ensure that AVMs were correctly identified. We observed 
that latex was retained within arterial vessels of skin, 
gastrointestinal tract, spleen, and kidney vasculature and 
rarely transferred to veins of these organs in either control 
or Eng-iKOe mice, consistent with the general absence of 
AVMs following loss of endothelial ENG (Online Table IV 
and Online Figure IVB). Strikingly, however, AVMs were 
consistently and reproducibly observed in vessels asso-
ciated with the cartilage of the pubic symphysis within 1 
week of ENG depletion in both male and female mice 
(Figure 4A and 4B; Online Table IV). These vessels were 
over 3× increased in diameter compared with control 
vessels in the same region (Figure 4C and 4D). There 
was no loss of vascular smooth muscle, which appeared 
to extensively coat these enlarged vessels (Figure 4F).
To investigate possible factors driving the formation of 
these AVMs, we first confirmed that baseline ENG levels 
in the pubic symphysis are similar to other tissues (Online 
Figure IC). We then looked at circulating VEGF (vascu-
lar endothelial growth factor) concentrations, as these 
have previously been reported to be increased in HHT 
patients.26 However, circulating VEGF levels were simi-
lar in Eng-iKOe and control mice (Figure 4G) consistent 
with the idea that no systemic proangiogenic stimulus was 
present in Eng-iKOe adult mice. We next considered there 
might be a local angiogenic stimulus in the vicinity of the 
pubic symphysis. We found this cartilage to have no differ-
ence in TGFβ1 expression between control and Eng-iKOe 
(Online Figure ID), but it had significantly increased VEGF 
levels compared with other organs (liver, heart, brain, and 
lung) in line with the known hypoxic properties of cartilage 
tissue27 (Figure 4H). However, this is an unusual region 
of fibrocartilage that is unprotected by a synovial capsule 
and has a highly intimate association with the feeding vas-
culature (Online Figure VA).28 This contrasts to joint carti-
lage where blood vessels are adjacent to but not intimately 
embedded within the cartilage (Online Figure VB). There-
fore, blood vessels within fibrocartilage of the pubic sym-
physis would normally be exposed to increased levels of 
VEGF and require tight regulation of the VEGF response. 
As ENG is a coreceptor for BMP9—a circulating vascu-
lar quiescent factor that antagonizes the proangiogenic 
effects of VEGF29,30—we questioned whether exagger-
ated endothelial responses to VEGF signaling occurred 
in the absence of ENG and could be driving de novo vas-
cular remodeling in mature adult vasculature of the pelvic 
region. To investigate EC autonomous defects, ECs were 
cultured from Rosa26-CreERT2;Engfl/fl mice as described 
previously.31,32 Transient treatment with 4-hydroxytamoxi-
fen was used to deplete ENG (Figure 5A). ENG-depleted 
ECs showed reduced basal expression of VEGFR2 
(VEGF receptor 2) and reduced VEGFR2 phosphorylation 
in response to VEGF stimulation (Figure 5B through 5D), 
in agreement with a previous report.33 Eng-iKOe ECs also 
appear to have increased basal pAKT (phospho-protein 
kinase B) levels (Figure 5E and 5F) that may promote 
their increased survival. However, most striking was an 
amplified pERK (phospho-extracellular signal-regulated 
kinase) response to VEGF stimulation in Eng-iKOe ECs 
(Figure 5G and 5H). This was also confirmed in vivo with 
significantly increased pERK staining in ECs of Eng-iKOe 
pubic symphysis compared with controls (Figure 5I and 
5J). As phosphorylation of ERK (extracellular signal-regu-
lated kinase) is associated with increased cell proliferation, 
we evaluated this property and found there was a signif-
icant increase in EC proliferation in AVMs of the pubic 
symphysis of Eng-iKOe mice (Figure 6A and 6B) that was 
not seen in brain ECs (Online Figure VI). There was also 
a trend toward increased EC size in vessels of the pubic 
symphysis. Taking this together, we concluded that loss of 
endothelial ENG resulted in increased sensitivity to VEGF 
that led to AVMs promoted by increased EC prolifera-
tion. In light of this finding, we reasoned that inhibition of 
VEGF signaling should reduce the incidence and severity 
of AVMs in Eng-iKOe mice and improve cardiac outcomes. 
In line with this idea, we found that short-term treatment 
with anti-VEGFR2 antibody DC101 (40 mg/kg) given to 
mice after ENG knockdown completely prevented AVM 
formation (Figure 7A through 7C). In addition, longer term 
studies using a similar DC101 treatment ameliorated the 
abnormal HOHF cardiac phenotype of Eng-iKOe mice. 
Cardiac stroke volumes and adverse remodeling of both 
cardiac ventricles and cardiac hypertrophy were all reduced 
in DC101-treated Eng-iKOe mice compared with those 
treated with nonspecific IgG (Figure 7D through 7F). Our 
data, therefore, support the concept that ENG is required 
to maintain endothelial quiescence in adult life where it 
acts to counter an overexuberant endothelial prolifera-
tion response to VEGF signaling, thereby protecting the 
vasculature against development of AVMs. Furthermore, 
rapid development of peripheral AVMs in the absence of 
endothelial ENG has a major effect on the heart leading 
to a rapid drop in aortic BP, increased venous return to 
the heart, and an increased cardiac output that invariably 
progresses to HOHF (Figure 8).
DISCUSSION
We show for the first time that endothelial ENG is essen-
tial in normal adult life to maintain vascular architecture 
and cardiac function. We demonstrate rapid development 
of large pelvic AVMs following loss of ENG in adult ECs 
exposed to endogenous VEGF in the noncapsulated 
fibrocartilage of the pelvic symphysis. These enlarging 
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Figure 4. Rapid development of arteriovenous malformations (AVMs) in association with pubic symphysis following endothelial 
cell–specific ENG (endoglin) deletion in adult mice.
A, Ventral vessels of the pubic symphysis in control (left) and Eng-iKOe (right) mice, following systemic perfusion with latex (blue). Scale bar=1 mm. B, 
Area occupied by latex perfused vessels as a proportion of the total pubic symphysis area (marked by dotted lines) is significantly greater in Eng-iKOe 
mice compared with controls. Data were analyzed by Student unpaired t test (n=5/group). C, Pubic symphysis of control or Eng-iKOe mice, stained for 
CD31 (cluster of differentiation 31) or YFP (yellow fluorescent protein) to visualize the vasculature. Upper panels (scale bar=1 mm). Bottom panels (scale 
bar=200 µm) correspond to boxed areas of upper panels (scale bar=1 mm). D, Quantification of vessel diameters (vessel area/vessel length, averaged 
across individual vessels, excluding capillaries with a diameter <8 µm) of control (n=7) and Eng-iKOe (n=6) mice reveals increased vessel size following 
ENG deletion. Data analyzed by Mann-Whitney U test. E, Trend toward reduced number of branch points following ENG deletion (n=4–6 mice). Data were 
analyzed by Student unpaired t test with Welch correction. F, Staining for αSMA (alpha smooth muscle actin; white) and CD31 (cluster of differentiation 
31; magenta) reveals extensive coverage of AVMs by αSMA-positive cells. Scale bar=50 µm. G, No difference in circulating VEGF (vascular 
endothelial growth factor) protein was observed between control and Eng-iKOe mice 5 wk after ENG depletion. Data were analyzed by Mann-Whitney 
U test (n=11–13/group). H, Expression of Vegfa transcripts assessed by quantitative polymerase chain reaction is significantly higher in pubic symphysis 
cartilage compared with other tissues in normal control mice (n=3–5/group). Data were analyzed by 1-way ANOVA with Bonferroni correction.
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AVMs lead to loss of aortic BP and increased cardiac fill-
ing pressure, which drives stretching of the myocardium 
during diastole and increased stroke volume in accor-
dance with the Frank-Starling law. The resultant pro-
gressive ventricular enlargement and high cardiac output 
ultimately leads to reduced ejection fraction and heart 
failure. These effects on the heart are similar to those 
seen in patients given surgical arteriovenous fistulas to 
initiate kidney dialysis.34
A small number of HHT patients develop HOHF 
because of left-to-right shunting of blood through major 
hepatic AVMs, but these are rare and more frequently 
seen in ALK1 (HHT2) patients than in ENG (HHT1) 
patients, for reasons that are not yet understood.23 In 
agreement with the low clinical prevalence in HHT1, 
there was no evidence of hepatic AVMs following loss of 
endothelial ENG in our model. We observe a novel pel-
vic anatomic location for AVMs that may also be highly 
relevant in humans with HHT; there have been limited 
reports of pelvic AVMs in HHT patients,35 but pelvic 
AVMs are not yet screened for in HHT. Although chal-
lenging to diagnose due to their deep location, pelvic 
AVMs are important to evaluate in patients as they carry 
a high risk for developing HOHF.36–38
Furthermore, as HHT1 patients carry one wild-type 
copy of the ENG gene, the current premise is that a sec-
ond hit (somatic loss of function mutation in normal ENG 
allele) is required to generate a vascular location that is 
at risk for detrimental remodeling to generate AVMs.13,39 
In addition, the vascular lesions in HHT patients generally 
develop in tissues exposed to environmental or inflam-
matory insults (lung, skin, and gastrointestinal tract) and 
liver (responsible for removing toxins of environmental 
origin). This complex pathogenesis explains the variability 
of clinical symptoms even within the same HHT1 fam-
ily carrying the same ENG mutation. In other words, the 
exact site and timing of lesions is unpredictable because 
of the timing of the second hit (random stochastic muta-
tion event) and the subsequent exposure to an inflam-
matory or other environmental stimulus that promotes 
angiogenesis; for example, macrophages secrete abun-
dant VEGF protein. Therefore, although our model does 
not recapitulate the usual tissue specificity of HHT, the 
factors driving the formation of AVMs are the same. In 
the mouse model, loss of ENG occurs after tamoxifen 
treatment, and the environmental proangiogenic trigger 
is the local high level of VEGF within the fibrocartilage. 
Therefore, the clinical significance of our findings is that 
HHT1 patients with a second genetic hit in the ENG 
gene in any tissue exposed to high levels of VEGF will 
develop AVMs.
VEGF is an important protein produced in the natu-
rally hypoxic cartilage tissue, where it acts as a survival 
factor for chondrocytes.40,41 Most cartilage is enclosed 
within a synovial capsule, but the pubic symphysis is an 
unusual fibrocartilage with intimate association of the 
vasculature and cartilage tissue.28 The evidence we show 
here links the naturally high endogenous VEGF levels in 
the exposed cartilage of the pubic symphysis, combined 
with the altered VEGF response of ENG-deficient ECs, 
to drive increased EC proliferation leading to large AVMs 
in the pelvic region and consequent HOHF. Furthermore, 
we show for the first time that treatment with DC101 to 
target VEGFR2 effectively protects against development 
of AVMs and reduces the detrimental effects of ENG 
loss on heart function.
A degree of serendipity led to the realization that tar-
geting VEGF signaling had potential value in treating 
HHT patients. Anti-VEGFA therapy (bevacizumab) origi-
nally given to HHT patients for concurrent cancer led 
to a marked improvement of HHT disease symptoms42,43 
and was followed up recently in a successful phase 2 
clinical trial in a small number of HHT2 patients with 
HOHF.44 However, there is little understanding of the 
molecular interaction of VEGF signaling and disrupted 
BMP9 signaling in HHT, which is essential to optimize 
and improve these therapies. We have recently shown 
that reduced VEGFR1 levels exacerbate HHT symp-
toms,45 in line with the current concept that VEGFR1 
normally acts as a ligand sink to divert VEGFA signaling 
away from VEGFR2. We now provide a valuable model 
to test and optimize therapeutic targeting of the VEGF 
signaling pathway in HHT disease.
Our previous work suggested altered VEGFR2 mem-
brane recycling kinetics associated with ENG-depleted 
ECs.8 Here, we additionally observe reduced VEGFR2 
receptor levels in ENG-deficient ECs similar to a pre-
vious report33 and also observed in SMAD4 (moth-
ers against decapentaplegic homolog 4) deficient ECs 
in vivo in a model that develops AVMs in the neonatal 
retina.46 Downregulation of VEGFR2 expression in ECs 
may reflect an adaptation to the increased sensitivity to 
VEGF signaling in the absence of ENG. We show here 
for the first time that ENG-depleted ECs in vitro show 
an exaggerated pERK response to VEGF compared with 
controls, and this increased pERK response was con-
firmed in the enlarged vessels of the Eng-iKOe pubic 
symphysis in vivo. Increased pERK activity likely drives 
the increased EC proliferation associated with AVM for-
mation. Intriguingly increased ERK activity in ECs is also 
associated with spontaneous brain AVMs because of 
somatic activating mutations in KRAS (Kirsten rat sar-
coma viral oncogene homolog)47 and may represent a 
unifying mechanism for AVM pathogenesis.
ENG is required to promote BMP9 signaling in the 
context of blood flow,48 and BMP9 circulates in an active 
form in vivo,49 although more recent data suggest its 
active form is a BMP 9/10 complex.50 Our data suggest 
that ENG-mediated BMP 9/10 signaling counters the 
VEGF response to reduce pERK responses and protect 
the vasculature. A recent report showed that a mini-
mum of 2-hour preincubation of cells with BMP9 was 
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Figure 5. Endothelial cells (ECs) show altered VEGF (vascular endothelial growth factor) signaling responses following loss of 
ENG (endoglin).
A, ECs cultured from Rosa26-CreERT2;Engfl/fl mice were transiently exposed to 4OH-tamoxifen to deplete ENG protein, which is measured by 
Western blot. Data were analyzed by Student unpaired t test (n=3). B–D, Cells exposed to VEGF (10 ng/mL) for 0, 5, 10, and 30 min and assessed 
by Western blot show a reduced VEGFR2 (VEGF receptor 2) phosphorylation response and reduced overall VEGFR2 levels compared with control 
ECs. E and F, Basal pAKT (phospho-protein kinase B) activity appears enhanced in Eng-iKO ECs compared with controls. G and H, Eng-iKO ECs 
have an increased and prolonged pERK (phospho-extracellular signal-regulated kinase) response compared with control cells. Molecular weights 
of named proteins are predicted based on molecular weight standards. Data in C, D, F, and H were analyzed using 2-way ANOVA with Bonferroni 
correction. Asterisks (*) indicate significant changes with respect to baseline for each genotype, while hashes (#) indicate significant differences 
between control and Eng-iKO ECs; the full set of P is summarized in Online Table VI (n=3–5/group). I, Increased levels of pERK in ECs of pubic 
symphysis of Eng-iKOe compared with control mice (scale bar=10 µm). J, Quantification of pERK vascular coverage from individual vessels from 
control (6 mice, n=19 vessels) and Eng-iKOe (4 mice, n=35 vessels) mice. Data analyzed by Mann-Whitney U test. AKT indicates protein kinase 
B; CD31, cluster of differentiation 31; and ERK, extracellular signal-regulated kinase.
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required to block VEGF-stimulated cell responses,51 sug-
gesting there are yet unidentified downstream factors 
responsible for ENG/ALK1/BMP9 regulation of the EC 
responses to VEGF.
Recent work revealed PI3K (phosphoinositide 
3-kinase) signaling defects in response to VEGF in the 
neonatal retina when ALK1 levels are reduced,51,52 but 
targeting VEGFR2 did not protect against AVMs.52 Simi-
larly, targeting VEGFR2 in the Eng-iKOe neonatal model 
did not significantly reduce the number of arteriovenous 
shunts in the neonatal retina but did reduce their diam-
eter.8 However, disrupting VEGF signaling interrupts the 
entire programme of vessel development in the neona-
tal retina and highlights the advantage of using an adult 
model to evaluate protective therapies in adult HHT 
patients. Furthermore, we and others have shown that 
endothelial-specific, or total, depletion of ALK1 in adult 
life leads to caecal bleeding, anemia, and rapid mortal-
ity.21,53,54 Pelvic AVMs were not reported in these stud-
ies but may have been present, although challenging to 
dissect the relative contribution of anemia and AVMs on 
heart pathophysiology of Alk1-iKO mice, while their rapid 
mortality limits longitudinal studies of disease progres-
sion and therapeutic interventions.
There is a growing interest in using anti-ENG 
(TRC105) antibody therapy to treat patients with can-
cer,55 but this treatment leads to development of clinical 
symptoms typical of HHT such as telangiectases.56 We 
suggest that patients on anti-CD105 therapy are also at 
increased risk of developing HOHF, and, therefore, heart 
Figure 6. Endothelial cell (EC) proliferation of the adult vasculature is promoted by endoglin deletion.
A, Vessels of the pubic symphysis of control (top) and Eng-iKOe (bottom) mice, exposed to repeated 5-ethynyl-2-deoxyuridine (EdU) injections 
over 2 wk, stained for CD31 (cluster of differentiation 31) or YFP (yellow fluorescent protein; ECs, white), ERG (erythroblast transformation-
specific transcription factor; EC nuclei, red), and EdU (proliferating cells, green). Left, Merged overviews. Scale bars=50 µm. Right, Boxed areas 
in left. Scale bars=20 µm. Yellow dotted lines outline the vasculature, and white dotted lines indicate proliferating ECs (ERG+ and EdU+, double 
positive). B, Quantification of accumulated EC proliferation over 2 wk demonstrates an increase from 31% proliferating ECs in control (n=4 mice) 
to 45% in Eng-iKOe (n=4 mice). Data were analyzed by Student unpaired t test. C, Quantification of average EC size calculated from the number 
of ERG+ cells per vessel shows a trend toward an increased EC size in Eng-iKOe mice (n=6) compared with controls (n=7). Data were analyzed 
by Mann-Whitney U test.
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Figure 7. Anti-VEGFR2 (VEGF receptor 2) therapy protects against arteriovenous malformations (AVMs) and high-output 
heart failure in Eng-iKOe mice.
A, Adult control and Eng-iKOe mice were treated with tamoxifen (2 mg/d for 5 d) and DC101 every other day for 8 d. B, Tissue was 
harvested following latex perfusion at day 10, and DC101 treatment completely abrogated AVM formation in the pelvic region of Eng-iKOe 
mice. Scale bar=0.8 mm. C, Quantitation of perfused vessels in pelvic area (n=3–5/group). D, Adult mice were treated with tamoxifen (2 
mg/d for 5 d), and DC101 (or a nonspecific IgG) was given twice weekly from day 8 for 5 wk. E, Cardiac magnetic resonance imaging 
(MRI) analysis revealed that DC101 treatment improved cardiac function in Eng-iKOe mice and the detrimental cardiac remodeling 
parameters (end systolic volume, end diastolic volume, and stroke volume) were all significantly protected by DC101 treatment (n=3–6/
group). F, Heart mass of Eng-iKOe mice was significantly reduced by DC101 treatment (n=6/group). All data were analyzed by 2-way 
ANOVA with Bonferroni correction.
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function and AVM screening will be critical to ensure car-
diovascular function is protected in these patients.
The model described here shows 100% penetrance 
of AVM development at a reproducible site in a reproduc-
ible time frame in adult mice. This represents a power-
ful new adult model of HHT to investigate cellular and 
molecular changes that underlie AVM formation and 
offers novel opportunities for drug testing.
The Eng-iKOe mouse also provides a powerful 
research tool to investigate the effect of volume over-
load on the heart and the responsive signals involved 
during cardiac remodeling and hypertrophy in a timed 
progressive manner. Previous models of HOHF require 
a major surgical procedure to create a direct connection 
between the abdominal aorta and inferior vena cava.57 
In contrast, our model is achieved by minimal interven-
tion with tamoxifen to generate rapid cardiac remodel-
ing and constitutes a valuable alternative for studies 
on progressive eccentric cardiac remodeling and high 
cardiac output associated with a range of clinical condi-
tions including AVMs, liver disease, and morbid obesity.58 
The data furthermore highlight the clinical importance of 
regional vascular abnormalities, in previously understud-
ied regions, on heart pathology. Our study demonstrates 
Figure 8. Schematic illustration of events leading to heart failure following endoglin depletion in endothelial cells. 
AVM indicates arteriovenous malformation; ENG, endoglin; LV, left ventricle; RV, right ventricle; VEGF, vascular endothelial growth factor; and 
VEGFR2, VEGF receptor2.
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for the first time that fluctuations of local endogenous 
VEGF levels can directly dictate the sensitivity to regional 
loss of ENG and subsequent impact on vascular integrity. 
This in turn strongly supports the hypothesis that ENG-
dependent AVMs in adult life are prone to develop in 
areas of high local VEGF expression, known to occur in 
infection, wounding, and in hypoxic conditions, and does 
not depend on a systemic increase in circulating VEGF. 
This new and highly reproducible model will also provide 
an invaluable resource that will be used for further inves-
tigating AVM pathobiology in HHT and evaluating drug 
treatments that prevent or rescue AVMs in adult life.
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